||United States : PANTHERx Specialty Pharmacy and RxCrossroads by McKesson Collaborate to Streamline the Channel for Precision Medicine Therapies
||PANTHERx Specialty Pharmacy, The Rare Disease Specialty Pharmacy, and RxCrossroads by McKesson, the leading commercial solutions partner for life sciences companies, announced their collaborative program to simplify the channel for precision medicine therapies. Recognizing a significant unmet need for cell and gene therapy programs, as well as a deep pipeline of products that are set to launch over the next several years, PANTHERx and RxCrossroads by McKesson are simplifying processes, coalescing strengths, gaining efficiencies, and creating a best-in-class portfolio for biopharma, provider, and payer partners.
PANTHERx is excited about partnering with RxCrossroads by McKesson in the rare disease and precision medicine space. This joint solution provides for more seamless and successful drug launches, increased speed to therapy, and enhanced patient satisfaction and outcomes, said Dr. Gordon J. Vanscoy, chairman and chief executive officer of PANTHERx Specialty Pharmacy. Patients are at the center of everything that we do at PANTHERx, so collaborating with a respected organization that shares our values is essential to us. We discovered a great match with RxCrossroads by McKesson, and we are confident that collectively, we will have measurable benefits for patients while enhancing the experiences of our biopharma partners.
RxCrossroads by McKesson is confident that together with PANTHERx we will produce a successful logistics solution to assist our life sciences partners in the rare disease and precision medicine space through significant phases of their product life cycle, said Kevin Kissling, vice president, Third-Party Logistics, RxCrossroads by McKesson. We are committed to providing innovative solutions for stakeholders, including those focused on rare diseases and precision medicines, which is why we are excited to be working with PANTHERx.
With combined core strengths in specialty pharmacy for rare diseases, third-party logistics, access & adherence solutions, and safety monitoring services, the parties are confident that the collaborative offering will be the go-to solution for biopharma companies desiring an all-in-one commercialization approach for cell and gene therapies.
BACK TO TOP